dimethylmalonic acid monochloride | 26576-31-8

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: dimethylmalonic acid monochloride
• 英文别名: 2,2-dimethyl-malonyl monochloride；dimethylmalonyl chloride；Dimethyl-malonsaeure-monochlorid；3-Chloro-2,2-dimethyl-3-oxopropanoic acid
• CAS: 26576-31-8
• 化学式: C₅H₇ClO₃
• 分子量: 150.562
• InChiKey: KIIZQJKLUQDWTH-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.4
• 重原子数：
  9
• 可旋转键数：
  2
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.6
• 拓扑面积：
  54.4
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  dimethylmalonic acid monochloride 在 磷酸酐 、 甲烷磺酸 作用下， 以 四氢呋喃 、 乙醚 为溶剂， 反应 16.5h， 生成 6-氯-3,3-二甲基喹啉-2,4-二酮
  参考文献：
  名称：

  Design and Synthesis of Thrombin Inhibitors:  Analogues of MD-805 with Reduced Stereogenicity and Improved Potency

  摘要：

  Mitsubishi's MD-805, a potent and selective inhibitor of thrombin which contains four stereogenic centers, has been the starting point for an optimization program. A systematic synthetic study resulted in thrombin inhibit;ors achiral at P2 and P3 but with a 10-fold increase in potency over the original lead. A number of 4-substituted piperidines were synthesized and examined as replacements for 2-carboxy-4-methylpiperidine at P2; 4-fluoroethylpiperidine (FEP) among others provided inhibitors (e.g. 45g) of increased potency. An enantioselective route was developed to 3(R)-methyl-1,2,3,4-tetrahydroquinolinesulfonyl chloride. Inhibitors containing this enantiomerically pure P3 (42d) had similar potency to the racemic material and provided support, with modeling studies, for the preparation of the gem 3,3-disubstituted compounds. A series of inhibitors containing the novel 3,3-dimethyl-1,2,3,4-tetrahydroquinolinesulfonyl (DMTHQS) P3 (Table 5) were synthesized and showed a similar activity profile as the monomethyl series. The combination of P3-DMTHQS, PB-FEP, and P1-arginine (45g) had a K-i of 6 nM (MD-805 K-i = 85 nM). In animal models of both venous and arterial thrombosis, one inhibitor (42e) was shown to produce a dose-dependent inhibition of thrombus formation that in some situations was superior to that of MD-805.

  DOI：

  10.1021/jm9811209
• 作为产物：
  描述：

  二甲基丙二酸 在 N,N-二甲基甲酰胺 草酰氯 作用下， 以 四氢呋喃 为溶剂， 反应 2.0h， 生成 dimethylmalonic acid monochloride
  参考文献：
  名称：

  Piperidine derivative and use thereof

  摘要：

  本发明提供了一种新颖的哌啶衍生物和含有该衍生物的催吐肽受体拮抗剂，以及由下式表示的化合物： 其中R1为羰胺甲基、甲磺酰乙基羰基等；R2为甲基或环丙基；R3为氢原子或甲基；R4为氯原子或三氟甲基；R5为氯原子或三氟甲基；以及由下式表示的基团： 是由下式表示的基团： 其中R6为氢原子、甲基、乙基或异丙基；R7为氢原子、甲基或氯原子；R8为氢原子、氟原子、氯原子或甲基；或3-甲基噻吩-2-基，并且其盐。

  公开号：

  US20080275085A1

文献信息

• NOVEL PYRIMIDINE DERIVATIVES
  申请人：Bolli Martin

  公开号：US20100234346A1

  公开（公告）日：2010-09-16

  The invention relates to novel pyrimidine derivatives, their preparation and their use as pharmaceutically active compounds. Said compounds particularly act as immunomodulating agents. Formula (I) wherein A represents Formula (II), Formula (III), Formula (IV), Formula (V), Formula (VI), Formula (VII), Formula (VIII) or Formula (IX)

  这项发明涉及新型嘧啶衍生物，它们的制备以及它们作为药用活性化合物的用途。这些化合物特别作为免疫调节剂。公式（I）其中A代表公式（II）、公式（III）、公式（IV）、公式（V）、公式（VI）、公式（VII）、公式（VIII）或公式（IX）。
• Arylalkane-sulfonamides having endothelin-antagonist activity
  申请人：——

  公开号：US20040102464A1

  公开（公告）日：2004-05-27

  The invention relates to novel aryl-alkane-sulfonamides and their use as active ingredients in the preparation of pharmaceutical compositions. The invention also concerns related aspects including processes for the preparation of the compounds, pharmaceutical compositions containing one or more of those compounds and especially their use as endothelin receptor antagonists.

  这项发明涉及新型芳基-烷基-磺酰胺及其在制备药物组合物中作为活性成分的用途。该发明还涉及相关方面，包括制备这些化合物的过程、含有其中一种或多种化合物的药物组合物，特别是它们作为内皮素受体拮抗剂的用途。
• Butyne diol derivatives
  申请人：——

  公开号：US20030087920A1

  公开（公告）日：2003-05-08

  The present invention relates to novel butyne diol derivatives of the general formula I and their use as active ingredients in the preparation of pharmaceutical compositions. The invention also concerns related aspects including processes for the preparation of the compounds, pharmaceutical compositions containing one or more compounds of the general formula I and especially their use as endothelin receptor antagonists.

  本发明涉及一般式I的新型丁炔二醇衍生物及其在制备药物组合物中作为活性成分的用途。该发明还涉及相关方面，包括制备化合物的过程、含有一种或多种一般式I化合物的药物组合物，特别是它们作为内皮素受体拮抗剂的用途。
• Aryl β-d-glucosides from Carica papaya fruit
  作者：Wilfried Schwab、Peter Schreier

  DOI：10.1016/0031-9422(88)80450-3

  日期：1988.1

  Abstract Benzyl β- d -glucoside, 2-phenylethyl β- d -glucoside, 4-hydroxyphenyl-2-ethyl β- d -glucoside and four isomeric malonated benzyl β- d

  摘要 苄基β-d-葡萄糖苷、2-苯乙基β-d-葡萄糖苷、4-羟基苯基-2-乙基β-d-葡萄糖苷和四种异构丙二酸苄基β-d-葡萄糖苷
• Novel arylethene-sulfonamides
  申请人：——

  公开号：US20030220359A1

  公开（公告）日：2003-11-27

  The invention relates to novel aryl-ethene-sulfonamides and their use as active ingredients in the preparation of pharmaceutical compositions. The invention also concerns related aspects including processes for the preparation of the compounds, pharmaceutical compositions containing one or more of those compounds and especially their use as endothelin receptor antagonists.

  这项发明涉及新颖的芳基乙烯磺酰胺及其在制备药物组合物中作为活性成分的用途。该发明还涉及相关方面，包括制备这些化合物的过程、含有其中一个或多个化合物的药物组合物，特别是它们作为内皮素受体拮抗剂的用途。